Literature DB >> 6770801

Acetazolamide dosage forms in the treatment of glaucoma.

F G Berson, D L Epstein, W M Grant, B T Hutchinson, P C Dobbs.   

Abstract

Patients with chronic glaucoma had a carefully scheduled series of intraocular pressure measurements before and after taking acetazolamide for one week at the following dosages: none, 500 mg of sustained-release capsules once a day, 500 mg of capsules twice a day, and 250 mg of tablets four times a day. A capsule taken once a day, which is better tolerated than one taken twice a day by some patients, offers a substantial pressure-lowering effect that lasts at least 23 hours, although the magnitude of the pressure lowering is less than with higher dosages. One capsule twice a day appears to be as effective in the regulation of IOP as one tablet four times a day. The 45% reduction in outflow pressure is achieved with an acetazolamide serum concentration in the range of 15 to 20 micrograms/mL.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6770801     DOI: 10.1001/archopht.1980.01020031041005

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  Comparison of the effect of acetazolamide tablets and sustets on diurnal intraocular pressure in patients with chronic simple glaucoma.

Authors:  P W Joyce; K B Mills
Journal:  Br J Ophthalmol       Date:  1990-07       Impact factor: 4.638

2.  Equivalence of conventional and sustained release oral dosage formulations of acetazolamide in primary open angle glaucoma.

Authors:  P W Joyce; K B Mills; T Richardson; G E Mawer
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

3.  Quantitative cerebrovascular reactivity MRI in mice using acetazolamide challenge.

Authors:  Zhiliang Wei; Yuguo Li; Xirui Hou; Zheng Han; Jiadi Xu; Michael T McMahon; Wenzhen Duan; Guanshu Liu; Hanzhang Lu
Journal:  Magn Reson Med       Date:  2022-06-17       Impact factor: 3.737

4.  Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence.

Authors:  Christopher N Schmickl; Robert L Owens; Jeremy E Orr; Bradley A Edwards; Atul Malhotra
Journal:  BMJ Open Respir Res       Date:  2020-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.